Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Please provide your email address to receive an email when new articles are posted on . Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous ...
BOSTON, April 2 (Reuters) - Abbott Laboratories Inc. said on Monday it has filed an application with U.S. and European regulators to market its rheumatoid arthritis drug Humira as a treatment for the ...
WASHINGTON (Reuters) - An advertisement for Abbott Laboratories' Humira minimizes the arthritis drug's risks while suggesting it can treat a wider range of patients than it is approved to treat, the U ...
Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name product (Humira) for patients either starting or switching treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback